Kythera Labs as a Qualified Entity

Certified by the Centers for Medicare & Medicaid Services (CMS) as a Qualified Entity in 2025, Kythera Labs is committed to empowering our customers with accurate insights into patient outcomes, referral dynamics, and healthcare market trends. By integrating comprehensive CMS data with our real-world claims data and platform, we bolster our clients’ ability to drive impactful, informed decisions.

2025 QE Report

Measurement Focus: Optic Nerve Evaluation in Patients with POAG

For our 2025 QE Report, Kythera Labs measured the rate of optic nerve evaluations for patients diagnosed with Primary Open-Angle Glaucoma (POAG) — the most common form of glaucoma and a leading cause of irreversible blindness.

Regular optic nerve evaluations are essential for early detection and monitoring, helping providers slow disease progression and preserve vision. Tracking how often these evaluations occur offers important insight into care quality and adherence to best practices.

‍

Key Insights Include:

• National performance rate of 53% across 3.4 million POAG patients and 40,985 providers.
• Demographic trends: Slight difference by gender (53% female, 54% male) and declining performance rates with increasing age.
• Payer comparison: Similar rates across major payer groups (~53–54%), with a significant drop to 24% in the “Other” category.
• Geographic variation: State rates ranged from 47% (CA) to 62% (ID, VT).
• Provider performance: 85% met expectations, with 16% falling below expected performance.

These findings help providers, payers, and policymakers identify gaps, benchmark performance, and improve glaucoma care delivery nationwide.

‍